newsfilter
← Latest News
GlobeNewswire·

Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia

  • Alps Group Inc announced a Research and Collaboration Agreement with Dr. Kong Wai Mun to launch an internal patient-derived organoid (PDO) program.
  • The program targets personalized cancer treatment & preclinical drug screening within the precision oncology sector.
  • The global human organoids market was valued at USD 91.8 million in 2026 & is projected to reach USD 349.5 million by 2036.
  • The global personalized cancer treatment market was valued at USD 222.54 billion in 2026 & is projected to reach USD 332.37 billion by 2030.
  • Alps aims to establish Malaysia's first clinically validated PDO platform with a regulatory pathway including MREC ethics approval & Medical Device Authority registration.
  • PDO technology involves growing 3D "mini-tumors" from patient tissue to evaluate therapy responses & reduce reliance on animal testing.
  • The company plans to create a national PDO biobank to support drug screening & licensing services while positioning Malaysia as a regional research hub.
  • Initial clinical interest has been identified across six major oncology centers in Malaysia.
  • Malaysia records approximately 51,650 new cancer cases annually, with 64.8% of cases diagnosed at advanced stages.
  • Dr. Kong Wai Mun stated that PDO platforms bridge laboratory research & clinical application to support personalized cancer care.